LIXTE Biotechnology Provides Update On Recent Activities and Developments
2024年8月19日 - 9:30PM
LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”)
(Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company
developing a new class of cancer therapy to enhance chemotherapy
and immunotherapy, today provided an update on the Company’s recent
activities.
“We are encouraged by the growing interest shown
by major pharmaceutical companies in our proprietary compound,
LB-100, as demonstrated by their support in clinical trial
collaborations,” said Bas van der Baan, LIXTE’s President and Chief
Executive Officer.
“Highlighting the Company’s recent progress is
our new agreement with The Netherlands Cancer Institute, supported
by F. Hoffmann- La Roche Ltd. (“Roche”), which is funding the
clinical trial in metastatic colorectal cancer and providing
atezolizumab (Tecentriq®, a PD-L1 inhibitor) through the imCORE
network, an academic industry collaboration that aims at
accelerating cancer immunotherapy research through institution
sponsored studies. Already underway is a proof-of-concept trial,
funded by GSK, of LB-100 plus GSK’s dostarlimab-gxly in ovarian
clear cell cancer.
“We are seeing encouraging results in the first
phase of our clinical trial to determine appropriate dosing and
toxicity for treating advanced soft tissue sarcomas with a
combination of LB-100 and standard-of-care chemotherapy and expect
to see the data from this first phase early in 2025. We are
exploring alternative sites, including international locations, for
our small cell lung cancer trial, following termination of that
clinical trial at City of Hope due to limited patient accrual,” Mr.
van der Baan added.
Recent Company Highlights:
- Collaboration with the Netherlands
Cancer Institute, supported by Roche, to conduct a new clinical
trial (NCT06012734 in clinicaltrials.gov) in immune therapy for
unresponsive (MSI Low) metastatic colorectal cancer. LIXTE is
providing its lead compound, LB-100, and Roche will provide
atezolizumab (Tecentriq®,a PD-L1 inhibitor). The clinical trial
will test recent findings that indicate that LB-100 increases
recognition of colorectal cancer cells by the immune system.
- Jan Schellens, M.D., Ph.D., joined
LIXTE as Chief Medical Officer effective August 1, 2024. Dr.
Schellens brings to the Company more than 25 years of clinical
experience as a medical oncologist, pharmacologist and clinical
pharmacologist, including more than two decades developing and
bringing new drugs to market. Co-author of more 900 publications in
peer-reviewed scientific journals, Dr. Schellens has held
leadership positions at the Netherlands Cancer Institute in
Amsterdam and the Dr. Daniel den Hoed Clinic-Erasmus University in
Rotterdam. He was professor of clinical pharmacology at Utrecht
University in the Netherlands, where he earned his M.D. degree, and
he served as a board member and Chief Medical Officer of Byondis
B.V. in Nijmegen, Netherlands. Dr. Schellens also earned a Ph.D.
degree in Pharmaceutical Sciences from Leiden University in Leiden,
Netherlands.
- New pre-clinical data in the
journal EMBO Reports shows that LIXTE’s lead compound, LB-100,
can turn immunologically “cold” tumors “hot,” potentially enhancing
the benefit of immunotherapy. In a paper titled, “The Phosphatase
Inhibitor LB-100 Creates Neoantigens in Colon Cancer Cells through
Perturbation of mRNA Splicing,” the article reported that
LIXTE’s collaborators from the Netherlands Cancer Institute have
demonstrated that treatment of cancer cells with LB-100 disrupts
the normal processing of the mRNA that encodes proteins, thereby
generating neo-antigens that are presented to the host immune
system. This new mechanism adds to several previous discoveries
showing that LB-100 sensitizes cancer cells to immune checkpoint
blockade.
- LIXTE will present at two upcoming
investor conferences: the 2004 Summit Summer 2024 Virtual
Conference, August 20, 2024, and the H.C. Wainwright 26th Annual
Global Investor Conference, September 9-11, 2024. Both conferences
will be virtual presentations.
About LIXTE Biotechnology Holdings,
Inc.
LIXTE Biotechnology Holdings, Inc. is a
clinical-stage pharmaceutical company focused on new targets for
cancer drug development and developing and commercializing cancer
therapies. LIXTE has demonstrated that its first-in-class lead
clinical PP2A inhibitor, LB-100, is well-tolerated in cancer
patients at doses associated with anti-cancer activity. Based on
extensive published preclinical data (see www.lixte.com), LB-100
has the potential to significantly enhance chemotherapies and
immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a
pioneering effort in an entirely new field of cancer biology
– activation lethality – that is advancing a new
treatment paradigm. LIXTE's new approach is covered by a
comprehensive patent portfolio. Proof-of-concept clinical trials
are currently in progress for colorectal, ovarian and sarcoma
cancers. Additional information about LIXTE can be found
at www.lixte.com.
Forward-Looking Statement
Disclaimer
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future activities, including the continuing development of
proprietary compounds, the planning, funding, coordination and
potential results of clinical trials, the patent and legal costs to
protect and maintain the Company's intellectual property worldwide,
and the Company’s ability to obtain and maintain compliance with
Nasdaq’s continued listing requirements, are all forward-looking
statements. These statements are generally accompanied by words
such as "intend," anticipate," "believe," "estimate,"
"potential(ly)," "continue," "forecast," "predict," "plan," "may,"
"will," "could," "would," "should," "expect" or the negative of
such terms or other comparable terminology.
The Company believes that the assumptions and
expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash resources, research results, competition from other
similar businesses, and market and general economic factors.
Readers are urged to read the risk factors set
forth in the Company’s filings with the United States Securities
and Exchange Commission at https://www.sec.gov. The Company
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
For more information about LIXTE, Contact:
info@lixte.com General Phone: (631) 830-7092; Investor Phone: (888)
289-5533
Or
PondelWilkinson Inc. Investor Relations
pwinvestor@pondel.comRoger Pondel: (310) 279-5965; Laurie Berman:
(310) 279-5962
Lixte Biotechnology (NASDAQ:LIXT)
過去 株価チャート
から 7 2024 まで 8 2024
Lixte Biotechnology (NASDAQ:LIXT)
過去 株価チャート
から 8 2023 まで 8 2024